20.64
+2.13%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Artivion
From its filings with the US Securities and Exchange Commission
Artivion is based in Kennesaw, Georgia and is incorporated in Delaware. Its shares trade on NYSE under the ticker AORT. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $441.3m and net income of $9.8m. At that date it held total assets of $884.8m and shareholders' equity of $448.2m. By business, Products brought in 78.4% of revenue, followed by Preservation services at 21.6%. By region, Foreign accounted for 51.5%, followed by UNITED STATES at 48.5%.
Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X® mechanical heart valves and related surgical products (“On-X” products), surgical sealants, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Aortic arch stent grafts include our E-vita® Open NEO, E-vita Open Plus, Arcevo™ LSA Hybrid Stent Graft System (“Arcevo LSA”), the Ascyrus Medical Dissection Stent (“AMDS”) hybrid prosthesis, the NEXUS ONETM (“NEXUS ONE”), NEXUS DUOTM (“NEXUS DUO”), and NEXUS TRETM (“NEXUS TRE”) aortic arch stent graft systems (the “NEXUS family of products”), and E-vita Thoracic 3G products. Abdominal stent grafts include our E-xtra Design Engineering, E-nsideTM, ArtivexTM, E-tegraTM, E-ventusTM BX, TuvaTM BX, and E-liacTM products. Surgical sealants include BioGlue® Surgical Adhesive (“BioGlue”) products. In addition to these four major product families, we sell or distribute PhotoFix® bovine surgical patches (“PhotoFix”) and CardioGenesis® cardiac laser therapy (prior to our abandonment of the business as of June 30, 2023).
Quoted from its 10-K, filed 18 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 12 Feb 1993
- Employees
- 1,800
- Website
- cryolife.com ↗
- Head office
- 1655 ROBERTS BOULEVARD N W, KENNESAW, GA, 30144
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. James MackinChairman of the Board, President, Chief Executive Officer, Director, since 2014$5.5m
- Mr. Lance BerryChief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Treasurer$2.6m
- Ms. Jean HollowaySenior Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary$1.5m
- Mr. John DavisSenior Vice President - Global Sales and Marketing$1.5m
- Dr. Marshall StantonSenior Vice President, Clinical Research and Chief Medical Officer$1.3m
- Ms. Amy HortonChief Accounting Officer, Vice President$1.1m
- Mr. Florian TyrsVice President - Global Operations
- Mr. Matthew GetzVice President - Human Resources
- Mr. Andrew GreenVice President - Regulatory Affairs
- Ms. Rochelle ManeyVice President - Global Quality
- Dr. Robert ThomsonVice President - Research & Development
- Mr. Jeffrey BurbankLead Independent Director$264,993
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 33
- Social
- 81
- Governance
- 54
- Women in the workforce
- 61%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CryoLife Inc has several strengths that contribute to its success in the market. These include:
Weaknesses
- Despite its strengths, CryoLife Inc also faces certain weaknesses that may hinder its growth and profitability. These weaknesses include:
Opportunities
- CryoLife Inc can leverage several opportunities in the market to further grow and enhance its position. These opportunities include:
Threats
- CryoLife Inc must also be cautious of potential threats that could impact its business operations and market position. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.